Effect of hexobendine on cerebral hemispheric blood flow and metabolism. Preliminary clinical observations concerning its use in ischemic cerebrovascular disease.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001565:Benzoates / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D001921:Brain / Q000378:metabolism*; D002245:Carbon Dioxide / Q000378:metabolism; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000097:blood / Q000188:drug therapy; D005029:Ethylenediamines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007238:Infarction / Q000188:drug therapy; D007275:Injections, Intravenous; D002546:Ischemic Attack, Transient / Q000097:blood / Q000188:drug therapy*; D007773:Lactates / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010101:Oxygen Consumption; D011773:Pyruvates / Q000378:metabolism; D012039:Regional Blood Flow / Q000187:drug effects; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use
D001565:Benzoates; D001786:Blood Glucose; D005029:Ethylenediamines; D007773:Lactates; D011773:Pyruvates; D014665:Vasodilator Agents; D002245:Carbon Dioxide